Zoetis (ZTS) Long-Term Deferred Tax (2012 - 2026)
Zoetis' (ZTS) quarterly Long-Term Deferred Tax came in at $591.0 million in Q1 2026, up 11.51% year-on-year from $530.0 million in Q1 2025, and down 7.08% on a QoQ basis from $636.0 million in Q4 2025.
Zoetis (ZTS) Long-Term Deferred Tax (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Long-Term Deferred Tax data on file, last reported at $591.0 million in Q1 2026.
- On a quarterly basis, Long-Term Deferred Tax rose 11.51% year-over-year to $591.0 million in Q1 2026; TTM through Mar 2026 was $591.0 million, a 11.51% increase from a year earlier, with the FY2025 full-year figure at $636.0 million, up 17.78% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $591.0 million, down from $636.0 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for ZTS reached as high as $636.0 million in Q4 2025 and fell as low as $103.0 million in Q1 2022.
- Historically, Long-Term Deferred Tax has averaged $338.5 million across 5 years, with a median of $232.0 million in 2024.
- Across the five-year window, Long-Term Deferred Tax rose 0.91% in 2022 and soared 162.14% in 2024, its largest moves.
- Year by year, Long-Term Deferred Tax stood at $173.0 million in 2022, then increased by 19.08% to $206.0 million in 2023, then surged by 162.14% to $540.0 million in 2024, then advanced by 17.78% to $636.0 million in 2025, then fell by 7.08% to $591.0 million in 2026.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $591.0 million in Q1 2026, $636.0 million in Q4 2025, and $587.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 591.00 Mn |
| Dec 31, 2025 | 636.00 Mn |
| Sep 30, 2025 | 587.00 Mn |
| Jun 30, 2025 | 617.00 Mn |
| Mar 31, 2025 | 530.00 Mn |
| Dec 31, 2024 | 540.00 Mn |
| Sep 30, 2024 | 409.00 Mn |
| Jun 30, 2024 | 366.00 Mn |
| Mar 31, 2024 | 232.00 Mn |
| Dec 31, 2023 | 206.00 Mn |
| Sep 30, 2023 | 190.00 Mn |
| Jun 30, 2023 | 192.00 Mn |
| Mar 31, 2023 | 161.00 Mn |
| Dec 31, 2022 | 173.00 Mn |
| Sep 30, 2022 | 111.00 Mn |
| Jun 30, 2022 | 110.00 Mn |
| Mar 31, 2022 | 103.00 Mn |
| Dec 31, 2021 | 100.00 Mn |
| Sep 30, 2021 | 110.00 Mn |
| Jun 30, 2021 | 103.00 Mn |